MIRM vs. PRTA, CNTA, XNCR, OCUL, COLL, IMNM, MNKD, ABCL, DCPH, and BLTE
Should you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Prothena (PRTA), Centessa Pharmaceuticals (CNTA), Xencor (XNCR), Ocular Therapeutix (OCUL), Collegium Pharmaceutical (COLL), Immunome (IMNM), MannKind (MNKD), AbCellera Biologics (ABCL), Deciphera Pharmaceuticals (DCPH), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical preparations" industry.
Mirum Pharmaceuticals (NASDAQ:MIRM) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.
Prothena received 493 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave Mirum Pharmaceuticals an outperform vote while only 70.60% of users gave Prothena an outperform vote.
97.1% of Prothena shares are owned by institutional investors. 24.1% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 28.1% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Mirum Pharmaceuticals presently has a consensus target price of $51.70, indicating a potential upside of 114.52%. Prothena has a consensus target price of $68.14, indicating a potential upside of 233.87%. Given Prothena's higher possible upside, analysts plainly believe Prothena is more favorable than Mirum Pharmaceuticals.
Prothena has lower revenue, but higher earnings than Mirum Pharmaceuticals. Prothena is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Mirum Pharmaceuticals has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.
Mirum Pharmaceuticals has a net margin of -86.33% compared to Prothena's net margin of -160.91%. Prothena's return on equity of -24.84% beat Mirum Pharmaceuticals' return on equity.
In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Prothena. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 5 mentions for Prothena. Prothena's average media sentiment score of 0.65 beat Mirum Pharmaceuticals' score of 0.29 indicating that Prothena is being referred to more favorably in the news media.
Summary
Prothena beats Mirum Pharmaceuticals on 10 of the 19 factors compared between the two stocks.
Get Mirum Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mirum Pharmaceuticals Competitors List
Related Companies and Tools
